Petros Pharmaceuticals, Inc.
PTPI · OTCMCIK 1815903fmd_0JEME8E833CR5RMHC2DZXMY9QDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 10 | 8 | 6 | 6 | 5 | – |
| Cost of revenue | 4 | 2 | 2 | 2 | 1 | – |
| Net interest income | – | – | 0 | 1 | 0 | 0 |
| Gross profit | 6 | 6 | 4 | 4 | 4 | – |
| Research and development | 0 | 2 | 2 | 2 | 3 | – |
| Selling, general and administrative | 16 | 16 | 12 | 9 | 5 | 5 |
| Total operating expenses | 23 | 24 | 24 | 18 | 5 | 5 |
| Compensation and benefits | – | – | – | 3 | 2 | – |
| Operating income | (17) | (18) | (20) | (14) | (5) | (5) |
| Interest expense | 3 | 0 | 1 | 1 | 1 | – |
| Interest and investment income | – | – | 0 | – | – | – |
| Other non-operating income (expense) | – | – | (0) | 5 | 4 | 0 |
| Income before taxes | (22) | (9) | (20) | (8) | (1) | (5) |
| Income tax expense | (1) | 0 | – | 0 | 0 | 0 |
| Net income from continuing operations | (21) | (9) | – | (8) | (1) | (5) |
| Net income | (21) | (9) | (20) | (8) | (14) | 2 |
| Net income to common shareholders | – | – | (20) | (14) | (27) | – |